gilead sciences international ltd.
gilead sciences international ltd. Company Information
Company Number
03177490
Website
www.gilead.comRegistered Address
flowers building, granta park, abington, cambridge, cambs, CB21 6GT
Industry
Other business support service activities n.e.c.
Telephone
01223897300
Next Accounts Due
September 2024
Group Structure
View All
Shareholders
gilead sciences ireland unlimited company 100%
gilead sciences international ltd. Estimated Valuation
Pomanda estimates the enterprise value of GILEAD SCIENCES INTERNATIONAL LTD. at £101m based on a Turnover of £79m and 1.28x industry multiple (adjusted for size and gross margin).
gilead sciences international ltd. Estimated Valuation
Pomanda estimates the enterprise value of GILEAD SCIENCES INTERNATIONAL LTD. at £131.2m based on an EBITDA of £13.1m and a 9.99x industry multiple (adjusted for size and gross margin).
gilead sciences international ltd. Estimated Valuation
Pomanda estimates the enterprise value of GILEAD SCIENCES INTERNATIONAL LTD. at £64.7m based on Net Assets of £25.5m and 2.54x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Gilead Sciences International Ltd. Overview
Gilead Sciences International Ltd. is a live company located in cambridge, CB21 6GT with a Companies House number of 03177490. It operates in the other business support service activities n.e.c. sector, SIC Code 82990. Founded in March 1996, it's largest shareholder is gilead sciences ireland unlimited company with a 100% stake. Gilead Sciences International Ltd. is a mature, large sized company, Pomanda has estimated its turnover at £79m with healthy growth in recent years.
Upgrade for unlimited company reports & a free credit check
Gilead Sciences International Ltd. Health Check
Pomanda's financial health check has awarded Gilead Sciences International Ltd. a 5 rating. We use a traffic light system to show it exceeds the industry average on 6 measures and has 2 areas for improvement. Company Health Check FAQs
6 Strong
2 Regular
2 Weak
Size
annual sales of £79m, make it larger than the average company (£3.8m)
£79m - Gilead Sciences International Ltd.
£3.8m - Industry AVG
Growth
3 year (CAGR) sales growth of 10%, show it is growing at a faster rate (3%)
10% - Gilead Sciences International Ltd.
3% - Industry AVG
Production
with a gross margin of 38.8%, this company has a comparable cost of product (38.8%)
38.8% - Gilead Sciences International Ltd.
38.8% - Industry AVG
Profitability
an operating margin of 13.1% make it more profitable than the average company (6.3%)
13.1% - Gilead Sciences International Ltd.
6.3% - Industry AVG
Employees
with 260 employees, this is above the industry average (24)
260 - Gilead Sciences International Ltd.
24 - Industry AVG
Pay Structure
on an average salary of £179.8k, the company has a higher pay structure (£50.5k)
£179.8k - Gilead Sciences International Ltd.
£50.5k - Industry AVG
Efficiency
resulting in sales per employee of £303.9k, this is more efficient (£157.9k)
£303.9k - Gilead Sciences International Ltd.
£157.9k - Industry AVG
Debtor Days
There is insufficient data available for this Key Performance Indicator!
- - Gilead Sciences International Ltd.
- - Industry AVG
Creditor Days
its suppliers are paid after 12 days, this is quicker than average (33 days)
12 days - Gilead Sciences International Ltd.
33 days - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- - Gilead Sciences International Ltd.
- - Industry AVG
Cash Balance
has cash to cover current liabilities for 65 weeks, this is more cash available to meet short term requirements (24 weeks)
65 weeks - Gilead Sciences International Ltd.
24 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 62.6%, this is a similar level of debt than the average (63.7%)
62.6% - Gilead Sciences International Ltd.
63.7% - Industry AVG
GILEAD SCIENCES INTERNATIONAL LTD. financials
Gilead Sciences International Ltd.'s latest turnover from December 2022 is £79 million and the company has net assets of £25.5 million. According to their latest financial statements, Gilead Sciences International Ltd. has 260 employees and maintains cash reserves of £26.9 million as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 79,011,000 | 75,663,000 | 70,602,000 | 59,575,000 | 55,158,000 | 55,854,000 | 43,101,000 | 35,051,000 | 31,275,000 | 28,607,000 | 22,836,000 | 18,613,000 | 14,150,000 | 11,401,000 |
| Other Income Or Grants | ||||||||||||||
| Cost Of Sales | ||||||||||||||
| Gross Profit | ||||||||||||||
| Admin Expenses | ||||||||||||||
| Operating Profit | 10,309,000 | 9,869,000 | 9,209,000 | 7,778,000 | 7,106,000 | 7,207,000 | 1,900,000 | 1,614,000 | 62,000 | 101,000 | -599,000 | 6,000 | -34,000 | -177,000 |
| Interest Payable | 806,000 | 877,000 | 947,000 | 1,011,000 | 6,000 | 35,000 | 4,000 | 2,000 | 6,000 | 7,000 | 53,000 | 109,000 | 8,000 | 0 |
| Interest Receivable | 469,000 | 13,000 | 86,000 | 226,000 | 81,000 | 29,000 | 36,000 | 38,000 | 26,000 | 113,000 | 10,000 | 7,000 | 0 | 2,000 |
| Pre-Tax Profit | 9,972,000 | 9,005,000 | 8,348,000 | 6,993,000 | 7,181,000 | 7,201,000 | 1,932,000 | 1,650,000 | 82,000 | 207,000 | -642,000 | -96,000 | -42,000 | -175,000 |
| Tax | -1,497,000 | -1,742,000 | -1,750,000 | -1,401,000 | -1,510,000 | -1,122,000 | -1,170,000 | -1,011,000 | -462,000 | -1,547,000 | 1,799,000 | -99,000 | -606,000 | -937,000 |
| Profit After Tax | 8,475,000 | 7,263,000 | 6,598,000 | 5,592,000 | 5,671,000 | 6,079,000 | 762,000 | 639,000 | -380,000 | -1,340,000 | 1,157,000 | -195,000 | -648,000 | -1,112,000 |
| Dividends Paid | 39,889,000 | 0 | 25,000,000 | 5,788,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Retained Profit | -31,414,000 | 7,263,000 | -18,402,000 | -196,000 | 5,671,000 | 6,079,000 | 762,000 | 639,000 | -380,000 | -1,340,000 | 1,157,000 | -195,000 | -648,000 | -1,112,000 |
| Employee Costs | 46,739,000 | 43,817,000 | 39,895,000 | 31,309,000 | 27,676,000 | 24,559,000 | 22,288,000 | 18,568,000 | 15,515,000 | 13,103,000 | 10,230,000 | 8,360,000 | 6,790,000 | 6,682,000 |
| Number Of Employees | 260 | 254 | 243 | 223 | 208 | 198 | 180 | 153 | 125 | 110 | 99 | 90 | 84 | 83 |
| EBITDA* | 13,128,000 | 14,351,000 | 11,793,000 | 10,630,000 | 8,140,000 | 7,800,000 | 2,234,000 | 1,824,000 | 373,000 | 425,000 | -317,000 | 138,000 | 197,000 | 98,000 |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 23,111,000 | 25,869,000 | 30,252,000 | 32,781,000 | 12,974,000 | 13,555,000 | 1,852,000 | 460,000 | 666,000 | 977,000 | 1,124,000 | 718,000 | 727,000 | 787,000 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments & Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debtors (Due After 1 year) | 3,384,000 | 2,112,000 | 1,141,000 | 941,000 | 840,000 | 1,256,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Fixed Assets | 26,495,000 | 27,981,000 | 31,393,000 | 33,722,000 | 13,814,000 | 14,811,000 | 1,852,000 | 460,000 | 666,000 | 977,000 | 1,124,000 | 718,000 | 727,000 | 787,000 |
| Stock & work in progress | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Debtors | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Group Debtors | 12,801,000 | 15,019,000 | 11,431,000 | 924,000 | 14,122,000 | 13,001,000 | 6,584,000 | 7,095,000 | 6,140,000 | 5,663,000 | 1,753,000 | 2,842,000 | 2,534,000 | 728,000 |
| Misc Debtors | 1,970,000 | 1,734,000 | 1,562,000 | 1,646,000 | 961,000 | 572,000 | 4,810,000 | 708,000 | 923,000 | 712,000 | 1,573,000 | 788,000 | 567,000 | 440,000 |
| Cash | 26,892,000 | 46,159,000 | 30,249,000 | 48,259,000 | 25,701,000 | 17,671,000 | 18,733,000 | 11,558,000 | 8,752,000 | 6,863,000 | 6,351,000 | 4,116,000 | 2,097,000 | 4,822,000 |
| misc current assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total current assets | 41,663,000 | 62,912,000 | 43,242,000 | 50,829,000 | 40,784,000 | 31,244,000 | 30,127,000 | 19,361,000 | 15,815,000 | 13,238,000 | 9,677,000 | 7,746,000 | 5,198,000 | 5,990,000 |
| total assets | 68,158,000 | 90,893,000 | 74,635,000 | 84,551,000 | 54,598,000 | 46,055,000 | 31,979,000 | 19,821,000 | 16,481,000 | 14,215,000 | 10,801,000 | 8,464,000 | 5,925,000 | 6,777,000 |
| Bank overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bank loan | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Creditors | 1,627,000 | 1,220,000 | 1,542,000 | 800,000 | 1,209,000 | 919,000 | 1,681,000 | 1,171,000 | 844,000 | 1,508,000 | 368,000 | 711,000 | 351,000 | 201,000 |
| Group/Directors Accounts | 1,913,000 | 561,000 | 979,000 | 2,937,000 | 75,000 | 1,769,000 | 306,000 | 0 | 197,000 | 366,000 | 86,000 | 132,000 | 293,000 | 34,000 |
| other short term finances | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 2,084,000 | 2,017,000 | 1,961,000 | 1,898,000 | 0 | 0 | 0 | 0 | 22,000 | 42,000 | 32,000 | 43,000 | 32,000 | 0 |
| other current liabilities | 15,819,000 | 15,949,000 | 13,609,000 | 10,439,000 | 15,896,000 | 16,499,000 | 13,921,000 | 7,049,000 | 6,518,000 | 5,326,000 | 5,357,000 | 5,510,000 | 4,187,000 | 2,606,000 |
| total current liabilities | 21,443,000 | 19,747,000 | 18,091,000 | 16,074,000 | 17,180,000 | 19,187,000 | 15,908,000 | 8,220,000 | 7,581,000 | 7,242,000 | 5,843,000 | 6,396,000 | 4,863,000 | 2,841,000 |
| loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 18,987,000 | 21,040,000 | 22,989,000 | 24,897,000 | 0 | 0 | 0 | 0 | 0 | 22,000 | 70,000 | 104,000 | 136,000 | 0 |
| Accruals and Deferred Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| provisions | 2,251,000 | 1,621,000 | 1,099,000 | 995,000 | 866,000 | 1,081,000 | 1,380,000 | 1,347,000 | 2,311,000 | 2,002,000 | 61,000 | 38,000 | 20,000 | 78,000 |
| total long term liabilities | 21,238,000 | 22,661,000 | 24,088,000 | 25,892,000 | 866,000 | 1,081,000 | 1,380,000 | 1,347,000 | 2,311,000 | 2,024,000 | 131,000 | 142,000 | 156,000 | 78,000 |
| total liabilities | 42,681,000 | 42,408,000 | 42,179,000 | 41,966,000 | 18,046,000 | 20,268,000 | 17,288,000 | 9,567,000 | 9,892,000 | 9,266,000 | 5,974,000 | 6,538,000 | 5,019,000 | 2,919,000 |
| net assets | 25,477,000 | 48,485,000 | 32,456,000 | 42,585,000 | 36,552,000 | 25,787,000 | 14,691,000 | 10,254,000 | 6,589,000 | 4,949,000 | 4,827,000 | 1,926,000 | 906,000 | 3,858,000 |
| total shareholders funds | 25,477,000 | 48,485,000 | 32,456,000 | 42,585,000 | 36,552,000 | 25,787,000 | 14,691,000 | 10,254,000 | 6,589,000 | 4,949,000 | 4,827,000 | 1,926,000 | 906,000 | 3,858,000 |
| Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||||||||
| Operating Profit | 10,309,000 | 9,869,000 | 9,209,000 | 7,778,000 | 7,106,000 | 7,207,000 | 1,900,000 | 1,614,000 | 62,000 | 101,000 | -599,000 | 6,000 | -34,000 | -177,000 |
| Depreciation | 2,819,000 | 4,482,000 | 2,584,000 | 2,852,000 | 1,034,000 | 593,000 | 334,000 | 210,000 | 311,000 | 324,000 | 282,000 | 132,000 | 231,000 | 275,000 |
| Amortisation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Tax | -1,497,000 | -1,742,000 | -1,750,000 | -1,401,000 | -1,510,000 | -1,122,000 | -1,170,000 | -1,011,000 | -462,000 | -1,547,000 | 1,799,000 | -99,000 | -606,000 | -937,000 |
| Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debtors | -710,000 | 4,731,000 | 10,623,000 | -12,412,000 | 1,094,000 | 3,435,000 | 3,591,000 | 740,000 | 688,000 | 3,049,000 | -304,000 | 529,000 | 1,933,000 | 1,168,000 |
| Creditors | 407,000 | -322,000 | 742,000 | -409,000 | 290,000 | -762,000 | 510,000 | 327,000 | -664,000 | 1,140,000 | -343,000 | 360,000 | 150,000 | 201,000 |
| Accruals and Deferred Income | -130,000 | 2,340,000 | 3,170,000 | -5,457,000 | -603,000 | 2,578,000 | 6,872,000 | 531,000 | 1,192,000 | -31,000 | -153,000 | 1,323,000 | 1,581,000 | 2,606,000 |
| Deferred Taxes & Provisions | 630,000 | 522,000 | 104,000 | 129,000 | -215,000 | -299,000 | 33,000 | -964,000 | 309,000 | 1,941,000 | 23,000 | 18,000 | -58,000 | 78,000 |
| Cash flow from operations | 13,248,000 | 10,418,000 | 3,436,000 | 15,904,000 | 5,008,000 | 4,760,000 | 4,888,000 | -33,000 | 60,000 | -1,121,000 | 1,313,000 | 1,211,000 | -669,000 | 878,000 |
| Investing Activities | ||||||||||||||
| capital expenditure | ||||||||||||||
| Change in Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| cash flow from investments | ||||||||||||||
| Financing Activities | ||||||||||||||
| Bank loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Group/Directors Accounts | 1,352,000 | -418,000 | -1,958,000 | 2,862,000 | -1,694,000 | 1,463,000 | 306,000 | -197,000 | -169,000 | 280,000 | -46,000 | -161,000 | 259,000 | 34,000 |
| Other Short Term Loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long term loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hire Purchase and Lease Commitments | -1,986,000 | -1,893,000 | -1,845,000 | 26,795,000 | 0 | 0 | 0 | -22,000 | -42,000 | -38,000 | -45,000 | -21,000 | 168,000 | 0 |
| other long term liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| share issue | ||||||||||||||
| interest | -337,000 | -864,000 | -861,000 | -785,000 | 75,000 | -6,000 | 32,000 | 36,000 | 20,000 | 106,000 | -43,000 | -102,000 | -8,000 | 2,000 |
| cash flow from financing | 7,435,000 | 5,591,000 | 3,609,000 | 35,101,000 | 3,475,000 | 6,474,000 | 4,013,000 | 2,843,000 | 1,829,000 | 1,810,000 | 1,610,000 | 931,000 | -1,885,000 | 5,006,000 |
| cash and cash equivalents | ||||||||||||||
| cash | -19,267,000 | 15,910,000 | -18,010,000 | 22,558,000 | 8,030,000 | -1,062,000 | 7,175,000 | 2,806,000 | 1,889,000 | 512,000 | 2,235,000 | 2,019,000 | -2,725,000 | 4,822,000 |
| overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| change in cash | -19,267,000 | 15,910,000 | -18,010,000 | 22,558,000 | 8,030,000 | -1,062,000 | 7,175,000 | 2,806,000 | 1,889,000 | 512,000 | 2,235,000 | 2,019,000 | -2,725,000 | 4,822,000 |
gilead sciences international ltd. Credit Report and Business Information
Gilead Sciences International Ltd. Competitor Analysis
Perform a competitor analysis for gilead sciences international ltd. by selecting its closest rivals, whether from the ADMINISTRATIVE AND SUPPORT SERVICE ACTIVITIES sector, other large companies, companies in CB21 area or any other competitors across 12 key performance metrics.
gilead sciences international ltd. Ownership
GILEAD SCIENCES INTERNATIONAL LTD. group structure
Gilead Sciences International Ltd. has no subsidiary companies.
Ultimate parent company
GILEAD SCIENCES INC
#0135210
GILEAD SCIENCES IRELAND UNLIMITED COMPAN
IE259755
2 parents
GILEAD SCIENCES INTERNATIONAL LTD.
03177490
gilead sciences international ltd. directors
Gilead Sciences International Ltd. currently has 4 directors. The longest serving directors include Ms Joanne Webbe (May 2022) and Ms Janet Dorling (Jun 2023).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Ms Joanne Webbe | 49 years | May 2022 | - | Director | |
| Ms Janet Dorling | 50 years | Jun 2023 | - | Director | |
| Mr Hans Stucker | 51 years | Jun 2023 | - | Director | |
| Mr John Jorden | United Kingdom | 40 years | Jun 2023 | - | Director |
P&L
December 2022turnover
79m
+4%
operating profit
10.3m
+4%
gross margin
38.8%
+3.34%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
December 2022net assets
25.5m
-0.47%
total assets
68.2m
-0.25%
cash
26.9m
-0.42%
net assets
Total assets minus all liabilities
gilead sciences international ltd. company details
company number
03177490
Type
Private limited with Share Capital
industry
82990 - Other business support service activities n.e.c.
incorporation date
March 1996
age
28
incorporated
UK
accounts
Full Accounts
ultimate parent company
previous names
nexstar pharmaceuticals international limited (September 2000)
euronex pharmacueticals limited (October 1997)
last accounts submitted
December 2022
address
flowers building, granta park, abington, cambridge, cambs, CB21 6GT
accountant
-
auditor
ERNST & YOUNG
gilead sciences international ltd. Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to gilead sciences international ltd..
gilead sciences international ltd. Companies House Filings - See Documents
| date | description | view/download |
|---|
